BMY achieved a dramatic turnaround with gross profit surging 283% to $30.7B and swinging from an $8.9B net loss to $7.1B profit, representing one of the most significant financial recoveries in recent pharmaceutical history.
This extraordinary financial transformation suggests BMY has successfully navigated previous challenges, likely through a combination of improved operational efficiency, successful product launches, and strategic portfolio optimization. The magnitude of improvement indicates fundamental business improvements rather than one-time accounting adjustments, positioning the company for sustained profitability.
BMY delivered exceptional financial performance with gross profit exploding from $8.0B to $30.7B (+283%) while achieving a remarkable $16B earnings swing from a $8.9B loss to $7.1B profit. The company simultaneously improved operational efficiency by reducing both SG&A expenses (-14%) and R&D spending (-11%), demonstrating disciplined cost management. Stockholders' equity strengthened to $18.5B (+13%), reflecting the company's improved financial foundation and signaling a complete business turnaround that should attract significant investor attention.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Net income grew 178.8% — bottom-line growth signals improving overall business health.
SG&A reduced 13.6% — improved cost efficiency or headcount reduction improving operating margins.
Equity base grew 13.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.
R&D spending cut 10.8% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →